Skip to main content
. 2020 Aug 29;29(12):105288. doi: 10.1016/j.jstrokecerebrovasdis.2020.105288

Table 2.

Results of Systematic Review with Cohort Studies of COVID-19 Positive Patients – Characteristics of Stroke, Treatment, and Mortality.

Study Ischemic, % (N) Days from COVID-19 symptom onset Laboratory data
Etiology
Treatment
Mortality, % (N)
D-dimer (μg/mL) CRP (mg/L) Cardiac troponin (ng/mL) Cryptogenic Cardioembolic Atherothrombic tPA Mechanical thrombectomy AC
Mao et al. 83.3% (5) 9 [range 1-18]* NA NA NA NA NA NA NA NA NA NA
Lodigiani et al. 100% (9) NA 3.6 [0.4, 6.3] NA NA NA NA NA 22.2% (2) 22.2% (2) 88.9% (8) NA
Yaghi et al. 100% (32) 10 [5, 16.5] 3.913 [2.549-10.000] 101.1 [38.8, 214.3] 0.7 [0.3125, 1.36]*3 65.6% (21) 21.9% (7) 6.3% (2) 12.5% (4) 21.9% (7) 78.1% (25) 37.5% (12)
Cantador et al. 100% (8) 6.3±5.4 2.589 [0.735, 8.156] 100.5 [27, 206] NA 25% (2) 25% (2) 37.5% (8) 12.5% (1) NA Prophylactic 37.5% (3), therapeutic 12.5% (2) 25% (2)
Romero Sanchez et al. NA 10⁎2 9.929±28.286 NA NA NA NA NA NA NA NA NA
Merkler et al. NA 16 [5, 28] 1.93 [0.559, 5.285] NA 0.03 [0.03, 0.09] 51.6% (16) 41.9% (13) NA 9.7% (3) 6.5% (2) NA 29% (9)
Klok et al. NA NA NA NA NA NA NA NA NA NA NA NA
Radmanesh et al. 100% (13) NA NA NA NA NA NA NA NA 23.1% (3) NA NA
Escalard et al. 100% (10) 6 [range 2-18]* NA NA NA NA NA NA 50% (5) 100% (10) NA 60% (6)
Kihira et al. NA NA NA NA NA NA NA NA NA NA NA NA

Days from COVID-19 symptom onset, D-dimer, C-reactive protein (CRP), cardiac troponin – shown as median [Q1, Q3] or mean±SD unless specified otherwise. *1 – specified as “range” in the original article. *2 - mean. *3 - Only 15 patients out of 32 patients had available value in the article. AC – anticoagulation; NA – non-applicable; tPA – tissue plasminogen activator.